Novo Nordisk wins Dutch court injunction in semaglutide patent infringement case
Reuters
The article is written in English. Novo Nordisk has secured a court injunction in the Netherlands, marking a significant legal victory in its ongoing patent infringement dispute over the drug semaglutide. This ruling aims to protect the company's intellectual property rights against competitors manufacturing generic versions of the medication.
All articles from 8 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.